[wpml_language_selector_widget]
[wpml_language_selector_widget]

Resources

Treatment Guidelines

Guidelines Link to guidelines
NCCN (V2.2024) https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf
ESMO Clinical Practice Guidelines (2020) https://www.annalsofoncology.org/article/S0923-7534(20)43163-1/fulltext

FDA approved drugs for NHL

Generic name Trade name Address
Acalabrutinib Calquence® https://www.calquence.com/
Axicabtagene ciloleucel Yescarta® https://www.yescarta.com/
Bendamustine Bendeka® https://www.bendeka.com/
Brentuximab vedotin Adcetris® https://www.adcetris.com/
Brexucabtagene autoleucel Tecartus® https://www.tecartus.com/
Copanlisib Aliqopa® https://www.aliqopa-us.com/
Cyclophosphamide Generic https://www.drugs.com/pro/cyclophosphamide.html
Doxorubicin Generic https://www.drugs.com/mtm/doxorubicin.html
Fludarabine Generic https://www.drugs.com/pro/fludarabine.html
Ibritumomab tiuxetan Zevalin® https://zevalin.com/wp-content/uploads/2019/04/PI-ZEVALIN-092019.pdf
Ibrutinib Imbruvica® https://www.imbruvica.com/
Lenalidomide Revlimid® https://www.revlimid.com/
Lisocabtagene maraleucel Breyanzi® https://www.breyanzi.com/
Loncastuximab tesirine-lpyl Zynlonta® https://www.zynlonta.com/
Ofatumumab Arzerra® https://www.us.arzerra.com/
Obinutuzumab Gazyva® https://www.gene.com/download/pdf/gazyva_prescribing.pdf
Pembrolizumab Keytruda https://www.keytruda.com/
Polatuzumab vedotin-piiq Polivy® https://www.polivy.com/
Prednisone Generic https://www.drugs.com/prednisone.html
Rituximab Rituxan® https://www.rituxan.com/
Selinexor Xpovio® https://www.xpovio.com/
Tafasitamab-cxix Monjuvi® https://www.monjuvi.com/
Tazemetostat Tazverik® https://www.tazverik.com/
Tisagenlecleucel Kymriah® https://www.kymriah.com/
Venetoclax Venclexta® https://www.venclexta.com/
Vincristine Vincasar® https://www.drugs.com/pro/vincasar-pfs.html
Zanubrutinib Brukinsa® https://www.brukinsa.com/

Ongoing clinical trials and new therapeutics for DLBCL1

Agent Agent type Combined agent Study
Odronextamab CD20xCD3 bispecific antibody – NCT03888105
Idelalisib PI3K inhibitor – NCT03576443
Copanlisib PI3Kα/δ inhibitor Nivolumab NCT03484819
Parsaclisib PI3Kδ inhibitor – NCT02998476
Parsaclisib PI3Kδ inhibitor R-CHOP NCT04323956
Parsaclisib PI3Kδ inhibitor Rituximab, bendamustine/ibrutinib NCT03424122
BR101801 PI3Kδ and DNA-PK dual inhibitor – NCT04018248
Umbralisib (TGR-1202) PI3Kδ and CK1 dual inhibitor Ublituximab, bendamustine NCT02793583
Everolimus mTORC1 inhibitor Lenalidomide NCT01075321
Temsirolimus mTORC1 inhibitor Rituximab, DHAP NCT01653067
Venetoclax BCL2 inhibitor – NCT01328626
Venetoclax BCL2 inhibitor Lenalidomide, obinutuzumab NCT02992522
Venetoclax BCL2 inhibitor Atezolizumab, obinutuzumab NCT03276468
Venetoclax BCL2 inhibitor RICE NCT03064867
Venetoclax BCL2 inhibitor DA-EPOCH-R NCT03036904
Venetoclax BCL2 inhibitor Obinutuzumab, rituximab, polatuzumab vedotin NCT02611323
Venetoclax BCL2 inhibitor Obinutuzumab NCT02987400
Entospletinib Spleen tyrosine kinase inhibitor R-CHOP NCT03225924
Ibrutinib BTK inhibitor ABT-199, rituximab NCT03136497
Ibrutinib BTK inhibitor ABT-199, prednisone, obinutuzumab, lenalidomide NCT03223610
Ibrutinib BTK inhibitor Loncastuximab tesirine NCT03684694
Ibrutinib BTK inhibitor Lenalidomide, rituximab NCT02077166
Ibrutinib BTK inhibitor R-ICE NCT02955628
Ibrutinib BTK inhibitor Buparlisib NCT02756247
Nemtabrutinib BTK inhibitor – NCT03162536
LOXO-305 BTK inhibitor Venetoclax, R-CHOP NCT03740529
DTRMWXHS-12 BTK inhibitor Everolimus, pomalidomide NCT04305444
Acalabrutinib BTK inhibitor – NCT02112526
Acalabrutinib BTK inhibitor RICE NCT03736616
Acalabrutinib BTK inhibitor DA-EPOCH NCT04002947
Acalabrutinib BTK inhibitor R-CHOP NCT03571308
Acalabrutinib BTK inhibitor pembrolizumab NCT02362035
Enzastaurin PKCβ inhibitor R-CHOP NCT03263026
Lenalidomide Immunomodulatory agent – NCT04150328
Lenalidomide Immunomodulatory agent MOR208 NCT02399085
Lenalidomide Immunomodulatory agent R-CHOP NCT00670358
Lenalidomide Immunomodulatory agent R-CHOP NCT00907348
Lenalidomide Immunomodulatory agent R-CHOP NCT01856192
Lenalidomide Immunomodulatory agent R-CHOP NCT02285062
Lenalidomide Immunomodulatory agent miniCHOP, subcutaneous rituximab NCT02128061
Lenalidomide Immunomodulatory agent Rituximab, ibrutinib NCT02636322
Itacitinib JAK1 inhibitor Parsaclisib NCT02018861
Itacitinib JAK1 inhibitor Ibrutinib NCT02760485
Ruxolitinib JAK1/2 inhibitor – NCT01431209
Valemetostat EZH1/2 dual inhibitor – NCT02732275
Tazemetostat EZH2 inhibitor – NCT01897571
Tazemetostat EZH2 inhibitor R-CHOP NCT02889523
Tazemetostat EZH2 inhibitor – NCT03456726
Tazemetostat EZH2 inhibitor – NCT02875548
Panobinostat HDACi – NCT01261247
Vorinostat HDACi R-CHOP NCT00972478
Chidamide HDACi – NCT03201471
Romidepsin HDACi 5-Azacitidine NCT01998035
Selinexor XPO1 inhibitor Venetoclax NCT03955783
Selinexor XPO1 inhibitor R-CHOP NCT03147885
Selinexor XPO1 inhibitor RICE NCT02471911

Bispecific Antibodies under investigation in R/R FL2

Agent Agent type Combined agent Study
Glofitamab CD3 (Fab) x CD20 (Fab x2) Fc BsAb IV Obinutuzumab NCT05783596
Mosunetuzumab CD3 x CD20 Knobs-into-holes Fc BsAb IV/SC Lenalidomide NCT04712097
Odronextamab CD3 x CD20 common LC Fc BsAb IV Lenalidomide NCT06149286
Epcoritamab DuoBody—CD3 x CD20 BsAb SC NCT05848765

Resources

Resource Address
American Cancer Society (ACS). What Is Non-Hodgkin’s Lymphoma? https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/what-is-non-hodgkin-lymphoma.html
ASCO Cancer.Net. Lymphoma – Non-Hodgkin. https://www.cancer.org/cancer/types/non-hodgkin-lymphoma.html
CancerCare https://www.cancercare.org/professionals
Leukemia & Lymphoma Society. Non-Hodgkin Lymphoma. https://www.lls.org/lymphoma/non-hodgkin-lymphoma
Lymphoma Research Foundation. Non-Hodgkin Lymphoma. https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/
Mayo Clinic. Non-Hodgkin’s lymphoma. https://www.mayoclinic.org/diseases-conditions/non-hodgkins-lymphoma/symptoms-causes/syc-20375680
MedlinePlus. Non-Hodgkin lymphoma. https://medlineplus.gov/ency/article/000581.htm
National Cancer Institute. Adult Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version. Updated May 18, 2023. https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq
National Comprehensive Cancer Network® (NCCN) https://www.nccn.org/home
US National Library of Medicine. Clinical Trials. https://clinicaltrials.gov/
All URLs accessed July 1, 2024

References

  1. Wang L, Li LR, Young KH. New agents and regimens for diffuse large B cell lymphoma. J Hematol Oncol. 2020;13:175. doi:10.1186/s13045-020-01011-z
  2. Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a novel, bivalent CD20-targeting T-cell engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: A phase I trial. J Clin Oncol. 2021;39:1959-1970. doi:10.1200/JCO.20.03175
  3. Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23:1055-1065. doi:10.1016/S1470-2045(22)00335-7
  4. Bannerji R, Arnason JE, Advani RH, et al. Odronextamab, a human CD20xCD3 bispecific antibody in patient with CD20-positive B-cell malignancies (ELM-1): Results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicenter, phase 1 trial. Lancet Haem. 2022;9:e327-e339. doi:10.1016/S2352-3026(22)00072-2
  5. Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An open-label, phase 1/2 study. 2021;398:1157-1169. doi:10.1016/S0140-6736(21)00889-8
  6. Cahill KE, Smith SM. Follicular lymphoma: A focus on current and emerging therapies. Oncology (Williston Park). 2022;36:97-106. doi:10.46883/2022.25920946

Defining NHL

Pathogenesis

Diagnosis & Staging

Treating & Managing NHL

Guidelines

Understanding AE’s

Patient Support Strategies

Resources

This activity is provided by Med Learning Group.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Copyright © 2024 NHL Strive. All Rights Reserved. Website by Divigner

Pin It on Pinterest

Directory
Scroll to Top

For optimized Clinical Trial Tracker use, please utilize Chrome or Firefox browsers